USPTO serial 86680065
Q2
Reviewed by CopyMark Law Group
Reg. 5950382Status 710
- Filing date
- Status date
- Registration date
- Dec 31, 2019
- Examiner
- MAYES, LAURIE ANN
- Law office
- PUBLICATION AND ISSUE SECTION
What this means
Status 710 means the registration was cancelled because a required Section 8 declaration of continued use was not filed within the deadline (including any grace period). The federal registration is no longer active. Evaluate filing a new application if you still use the mark, or petition if cancellation was erroneous. Consult counsel on remaining common-law rights.
Need help with Q2?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Q Squared Solutions Holdings LLC
Morrisville, NC, US
Q Squared Solutions Holdings LLC
Morrisville, NC, US
Q Squared Solutions Holdings LLC
Morrisville, NC, US
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Arlene D. Hanks
ARLENE D. HANKS Moore & Van Allen PLLC100 North Tryon StreetSuite 4700Charlotte, NC 28202-4003Goods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 035 | Computerized database management and data processing services in the pharmaceutical, pharmacogenomic, biomarker, biopharmaceutical, medical device and diagnostics fields; providing business information, namely, information related to regulatory approval and marketing of drugs, devices, health care or medical products and services, and biologics; none of the foregoing for use in the field of Medicare | SECTION 8 - CANCELLED | — |
| 042 | Clinical research and testing services, in the fields of clinical trials, health care products, pharmaceutical products, pharmacogenomics products, biomarker products, biopharmaceutical products, medical devices and diagnostics products; product development consultation in the fields of health care, medical products and devices; health care research and product development services; medical and laboratory testing services for research purposes; laboratory testing services for research purposes in the fields of health care, clinical trials, pharmaceutical, pharmacogenomics, biomarker, biopharmaceutical, medical device and diagnostics; consultancy in the design, planning and implementation project management of clinical trials; health care medical research consultancy; product development consultancy in the fields of medical diagnostics, medical devices, pharmacology, pharmacogenomics, biomarkers and biopharmaceutical research; managing, namely, monitoring, coordinating and implementing clinical studies being clinical trials on human subjects for others for research purposes; medical and scientific research in the fields of healthcare and medical diagnostics; providing temporary use of non-downloadable, web-based software application for providing access to information and data in the clinical trials, pharmaceutical, pharmacogenomic, biomarker, biopharmaceutical, medical device and diagnostics, life sciences, health management and disease management fields and for organizing and analyzing said data and information and preparing reports therefrom,; providing temporary use of non-downloadable software for providing, managing and analyzing laboratory clinical trial data and information in the fields of pharmaceutical, pharmacogenomic, biomarker, biopharmaceutical, medical device and diagnostics, life sciences, health management and disease management fields; providing temporary use of non-downloadable software that allows remote access to clinical trial peri- and post-approval laboratory data and information; providing temporary use of non-downloadable software for use in collecting and reporting medical data relating to patient medical conditions for research; providing scientific and medical research information relating to the development and validation of drugs, pharmaceutical products, medical products, medical devices and biologics; providing an internet website portal featuring scientific and medical research information in the fields of clinical trials, pharmaceutical research, pharmacogenomic and biomarker consultation, biopharmaceutical consultation, medical devices and diagnostics, life sciences research, and medical research; providing an online searchable database via the internet featuring medical and scientific research information in the fields of clinical trials, companion diagnostics, pharmaceutical research, pharmacogenomic and biomarkers, biopharmaceuticals, medical devices and diagnostics, life sciences research, and medical research; all of the foregoing relating to clinical trials, clinical research, medical and scientific laboratory services, biopharmaceutical, biomarker, diagnostics and medical product and device development, and research, testing, regulatory approval and commercialization of diagnostics, biopharmaceuticals, biomarkers and medical products and devices and none of the foregoing for use in the field of Medicare or related to Medicare or other governmental health programs | SECTION 8 - CANCELLED | — |
| 044 | Providing health and medical information; providing pharmaceutical information relating to diagnostic, prophylactic and therapeutic properties of pharmaceuticals; providing medical information relating to pharmacogenomics and biomarkers; health management and disease management medical information to others; medical evaluation services; medical consulting services in the fields of health care, medicine, life sciences, and pharmaceuticals, biopharmaceuticals, biomarkers, pharmacogenomics, medical device and diagnostics; providing an online interactive computer database in the field of healthcare featuring healthcare information; providing an Internet website portal featuring medical and healthcare information in the fields of medical services, health care, health management and disease management; providing an online searchable database via the internet featuring medical and healthcare information in the fields of medical services, medical devices and diagnostics, health care, health management and disease management; none of the foregoing for use in the field of Medicare | SECTION 8 - CANCELLED | — |
| 045 | Regulatory compliance research and consulting services in the fields of health care, clinical trials, development and testing of drugs, devices, biologics and methodologies used in the pharmaceutical industry, biotechnology industry and the medical device and diagnostics industry; consulting services in the fields of regulatory affairs, namely, regulatory compliance consulting in the field of prescription drug sampling; manufacturing compliance and validation procedures, namely, reviewing standards and practices to assure compliance with clinical trial regulations, medical and laboratory testing services; providing regulatory information, namely, providing regulatory compliance information regarding the examination and approval process of pharmaceutical, biotechnical, medical and diagnostic products and methodologies by governmental regulatory bodies; providing regulatory compliance consulting services relating to the development and validation of drugs, devices and biologics, namely, assisting others in implementing procedures that comply with regulatory requirements; none of the foregoing for use in the field of Medicare | SECTION 8 - CANCELLED | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by Q Squared Solutions Holdings LLC
- Other trademarks owned by Q Squared Solutions Holdings LLC
- Other trademarks owned by Q Squared Solutions Holdings LLC
- Other trademarks in Class 035
- Other trademarks in Class 042
- Other trademarks in Class 044
- Other trademarks in Class 045
- Similar marks named Q2
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Jul 10, 2026 | C8.. | CANCELLED SEC. 8 (6-YR) | — |
| Dec 31, 2024 | REM1 | COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED | — |
| Dec 31, 2019 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Nov 26, 2019 | SUNA | NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED | — |
| Nov 25, 2019 | CNPR | ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED | — |
| Nov 18, 2019 | SUPC | STATEMENT OF USE PROCESSING COMPLETE | — |
| Nov 13, 2019 | IUAF | USE AMENDMENT FILED | — |
| Nov 13, 2019 | EISU | TEAS STATEMENT OF USE RECEIVED | The applicant filed a Statement of Use with specimens showing the mark in actual commerce. The USPTO will review the filing for compliance. If accepted, the mark can proceed to registration; if deficient, the USPTO may issue a requirement or office action. |
| May 22, 2019 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| May 21, 2019 | EX5G | SOU EXTENSION 5 GRANTED | — |
| May 21, 2019 | AITU | CASE ASSIGNED TO INTENT TO USE PARALEGAL | — |
| May 17, 2019 | EXT5 | SOU EXTENSION 5 FILED | — |
| May 17, 2019 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Dec 19, 2018 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Oct 27, 2018 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Oct 25, 2018 | EX4G | SOU EXTENSION 4 GRANTED | — |
| Oct 25, 2018 | EXT4 | SOU EXTENSION 4 FILED | — |
| Oct 25, 2018 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| May 16, 2018 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| May 14, 2018 | EX3G | SOU EXTENSION 3 GRANTED | — |
| May 14, 2018 | EXT3 | SOU EXTENSION 3 FILED | — |
| May 14, 2018 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Nov 9, 2017 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Nov 7, 2017 | EX2G | SOU EXTENSION 2 GRANTED | — |
| Nov 7, 2017 | EXT2 | SOU EXTENSION 2 FILED | — |
| Nov 7, 2017 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| May 12, 2017 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| May 10, 2017 | EX1G | SOU EXTENSION 1 GRANTED | — |
| May 10, 2017 | EXT1 | SOU EXTENSION 1 FILED | — |
| May 10, 2017 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Nov 22, 2016 | NOAM | NOA E-MAILED - SOU REQUIRED FROM APPLICANT | A Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date. |
| Sep 27, 2016 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Sep 27, 2016 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Sep 7, 2016 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Aug 25, 2016 | PREV | LAW OFFICE PUBLICATION REVIEW COMPLETED | — |
| Aug 23, 2016 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Aug 18, 2016 | XAEC | EXAMINER'S AMENDMENT ENTERED | — |
| Aug 17, 2016 | ALIE | ASSIGNED TO LIE | — |
| Aug 17, 2016 | GNEN | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | — |
| Aug 17, 2016 | GNEA | EXAMINERS AMENDMENT E-MAILED | — |
| Aug 17, 2016 | CNEA | EXAMINERS AMENDMENT -WRITTEN | — |
| May 9, 2016 | GNFN | NOTIFICATION OF FINAL REFUSAL EMAILED | — |
| May 9, 2016 | GNFR | FINAL REFUSAL E-MAILED | A final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon. |
| May 9, 2016 | CNFR | FINAL REFUSAL WRITTEN | A final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon. |
| Apr 16, 2016 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Apr 15, 2016 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Apr 15, 2016 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Oct 20, 2015 | GPRN | NOTIFICATION OF PRIORITY ACTION E-MAILED | A priority action is a type of Office Action the USPTO treats as time-sensitive. It usually means the examining attorney needs a specific response or amendment quickly — often relating to a foreign priority claim or a formal requirement. Respond within the stated deadline. |
| Oct 20, 2015 | GPRA | PRIORITY ACTION E-MAILED | A priority action is a type of Office Action the USPTO treats as time-sensitive. It usually means the examining attorney needs a specific response or amendment quickly — often relating to a foreign priority claim or a formal requirement. Respond within the stated deadline. |
| Oct 20, 2015 | CPRA | PRIORITY ACTION WRITTEN | A priority action is a type of Office Action the USPTO treats as time-sensitive. It usually means the examining attorney needs a specific response or amendment quickly — often relating to a foreign priority claim or a formal requirement. Respond within the stated deadline. |
| Oct 12, 2015 | DOCK | ASSIGNED TO EXAMINER | — |
| Jul 8, 2015 | MPMK | NOTICE OF PSEUDO MARK E-MAILED | — |
| Jul 7, 2015 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Jul 4, 2015 | NWAP | NEW APPLICATION ENTERED | — |